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Abstract In hypoparathyroidism, inappropriately low levels
of parathyroid hormone lead to unbalanced mineral home-
ostasis. The objective of this study was to determine the
effect of recombinant human parathyroid hormone, rhPTH
(1–84), on phosphate and vitamin D metabolite levels in
patients with hypoparathyroidism. Following pretreatment
optimization of calcium and vitamin D doses, 124 patients in
a phase III, 24-week, randomized, double-blind, place-
bo-controlled study of adults with hypoparathyroidism
received subcutaneous injections of placebo or rhPTH(1–84)
(50 µg/day, titrated to 75 and then 100 µg/day, to permit
reductions in oral calcium and active vitamin D doses while
maintaining serum calcium within 2.0–2.2 mmol/L). Pre-
deﬁned endpoints related to phosphate homeostasis and
vitamin D metabolism were analyzed. Serum phosphate
levels decreased rapidly from the upper normal range and
remained lower with rhPTH(1–84) (P < 0.001 vs. placebo).
At week 24, serum calcium–phosphate product was lower
with rhPTH(1–84) vs. placebo (P< 0.001). rhPTH(1–84)
treatment resulted in signiﬁcant reductions in oral calcium
dose compared with placebo (P< 0.001) while maintaining
serum calcium. After pretreatment optimization, baseline
serum 25-hydroxyvitamin D (25[OH]D) and 1,25-dihy-
droxyvitamin D (1,25[OH]2D) levels were within the nor-
mal range in both groups. After 24 weeks, 1,25(OH)2D
levels were unchanged in both treatment groups, despite
signiﬁcantly greater reductions in active vitamin D dose in
the rhPTH(1–84) group. In hypoparathyroidism, rhPTH
(1–84) reduces serum phosphate levels, improves
calcium–phosphate product, and maintains 1,25(OH)2D and
serum calcium in the normal range while allowing sig-
niﬁcant reductions in active vitamin D and oral calcium
doses.
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Introduction
Hypoparathyroidism is a rare disorder of unbalanced
mineral homeostasis resulting from absent or inappropri-
ately low levels of endogenous parathyroid hormone (PTH)
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[1–3]. Although hypocalcemia is a classic hallmark of
hypoparathyroidism, hyperphosphatemia, and hypomagne-
semia may also occur [4]. PTH acts directly on bone,
increasing turnover, and resulting in the release of calcium
and phosphate into the circulation [4, 5]. In the kidney, PTH
stimulates renal reabsorption of calcium, promotes phos-
phate excretion in the urine, and enhances the conversion of
25-hydroxyvitamin D (25[OH]D) to the active 1,25-dihy-
droxyvitamin D (1,25[OH]2D) metabolite, which increases
transepithelial transport of dietary calcium and phosphate
from the intestine [4–6]. In concert, these effects help
maintain normal serum calcium and phosphate levels.
With standard conventional management, the goal is to
maintain serum calcium at the low end of the normal range
while attempting to avoid both hypocalcemia and hyper-
calciuria as well as hyperphosphatemia, which can increase
the calcium–phosphate product [4, 5]. Despite the clinical
feasibility of therapy with oral calcium and active vitamin D
(calcitriol or alfacalcidol), albeit used often in large amounts,
important complications can ensue. Conventional therapy
can lead to hypercalciuria, which in turn can result in
nephrolithiasis and nephrocalcinosis, and irreversible kidney
damage [4, 5, 7]. Active vitamin D metabolites do not replace
the phosphaturic action of PTH and might exacerbate
hyperphosphatemia by enhancing intestinal phosphate
absorption [4]. Elevated serum phosphate levels may increase
the serum calcium–phosphate product, thereby raising the
risk for precipitation of calcium–phosphate. In patients with
advanced renal disease, elevated serum phosphate levels and
higher serum calcium–phosphate product were associated
with coronary calciﬁcations and increased mortality risk
[8, 9]. In patients with hypoparathyroidism, calciﬁcation
complexes have been reported in soft tissues, particularly
the brain, lens, and kidney, but also the vasculature and
other tissues [5, 7, 10–12]. Recent guidelines recommend
maintaining calcium–phosphate product levels below
4.4 mmol2/L2 (55 mg2/dL2) to reduce the risk of ectopic
calciﬁcations and advise consideration of a low phosphate
diet and, in certain cases, phosphate binders as needed to
control phosphate levels [12–14].
In patients with hypoparathyroidism, daily subcutaneous
(SC) treatment with recombinant human PTH (rhPTH
(1–84), PTH rDNA; NATPARA®; Shire-NPS Pharmaceu-
ticals, Inc., Lexington, MA, USA) has the potential to
reproduce some of the physiologic effects of PTH compared
with conventional therapy, such as lowering serum phos-
phate levels, promoting conversion of 25(OH)D to active
1,25(OH)2D, and improving renal tubular reabsorption of
calcium. rhPTH(1–84) is identical to native human PTH
[15, 16]. Treatment of hypoparathyroidism with rhPTH
(1–84) has been studied in several recently published clin-
ical trials [16–21]. In short, these studies demonstrate that
treatment with rhPTH(1–84) is associated with reduced
requirements for oral calcium and active vitamin D while
maintaining control of symptoms, and some studies provide
evidence for improved quality of life. The pivotal registra-
tion study for rhPTH(1–84), REPLACE, was a 24-week,
randomized, double-blind, placebo-controlled, phase III,
multicenter study that demonstrated that once-daily SC
injections of rhPTH(1–84) reduced both oral calcium and
active vitamin D requirements by ≥50 % from baseline
levels while maintaining albumin-corrected total serum
calcium levels in the target range (1.9 mmol/L to laboratory
upper limit of normal) at Week 24 [19]. 53 % of patients
who received rhPTH(1–84) achieved this endpoint com-
pared with 2 % who received placebo (P< 0.0001). Com-
plete independence from calcitriol or alfacalcidol and
reduction of daily calcium doses to ≤500 mg/day while
maintaining serum calcium in the target range was achieved
by 43 % of the rhPTH(1–84) group compared with 5 % of
the placebo group (P< 0.0001).
In this report, we present additional relevant results from
the largest randomized, placebo-controlled trial completed
in this endocrine-deﬁciency disease population. This infor-
mation provides a greater understanding of the effects of
rhPTH(1–84) beyond the previously reported composite
primary endpoint of the REPLACE study [19]. Using pre-
deﬁned individual REPLACE clinical study exploratory
endpoints, relevant serum and urine data collected during
the trial were analyzed for the effects of rhPTH(1–84) on
phosphate homeostasis and vitamin D metabolism.
Materials and methods
Study design
Detailed inclusion and exclusion criteria have been reported
by Mannstadt et al. [19]. Brieﬂy, patients between 18 and
85-years-old were deﬁned as having hypoparathyroidism
based on hypocalcemia and documented PTH levels below
the lower limit of the normal range at least twice within the
previous 12 months [19]. The study was conducted in 32
outpatient centers in accordance with Good Clinical Prac-
tice guidelines and the Declaration of Helsinki, and all study
patients provided informed consent. This study is registered
with ClinicalTrials.gov (NCT00732615) and EU clinical
trials register (EudraCT 2008-005063-34).
During an optimization period over the ﬁrst 2–16 weeks
of the study, active vitamin D (calcitriol or alfacalcidol) and
calcium doses were adjusted, as previously described [19].
During the optimization phase, native vitamin D doses were
adjusted as follows: patients with serum 25(OH)D levels
below the lower limit of normal (<75 nmol/L) were sup-
plemented with vitamin D3 at 2000 IU/day until levels
reached the normal range (75 nmol/L‒250 nmol/L), patients
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with serum 25(OH)D levels in the normal range received
maintenance vitamin D3 at 400 IU/day, and patients with
serum 25(OH)D levels above the normal range did not
receive vitamin D3.
After calcium and active vitamin D doses were stable for
a 2-week period, which established the baseline doses,
patients were randomized in a 1:2 ratio to receive once-daily
SC injections of placebo or 50 μg rhPTH(1–84). The 24-
week treatment period began with a stepwise titration phase
that allowed for 2 uptitrations of rhPTH(1–84) dose, if
needed, to reduce active vitamin D ﬁrst and then oral cal-
cium, as previously described [19]. The titration phase was
followed by a maintenance phase for the remainder of the
treatment period; rhPTH(1–84) could be downtitrated at any
time, if necessary, but not uptitrated. Adjustments were
permitted in active vitamin D and oral calcium doses to
maintain serum calcium in the target range and to improve
hypercalciuria at any time during the treatment period.
During the treatment phase, patients received at least 400
IU/day of vitamin D3; patients with serum 25(OH)D levels
below the lower limit of normal received additional vitamin
D3 as necessary to bring levels into the normal range.
rhPTH(1–84) was discontinued at the conclusion of
24 weeks, whereby baseline oral calcium and active vitamin
D were resumed, and patients were followed up for
4 weeks.
Assessments
The assessments for serum phosphate levels were scheduled
at baseline and Weeks 1, 2, 3, 4, 5, 6, 8, 12, 16, 20, and 24,
and 24-hour urine phosphate measurements were done at
baseline and Weeks 3, 5, 6, 8, 12, 16, and 24. Serum
phosphate was measured 24 h after the last injection of
rhPTH(1–84) or placebo, as part of a 24-analyte serum
chemistry panel that required fasting for ≥8 h before testing.
Reported serum phosphate values in mg/dL were converted
to International System of Units (mmol/L) using a standard
conversion factor of 0.323 [22]. Serum levels of 25(OH)D
were assessed at baseline and 24 h after the last injection of
rhPTH(1–84) or placebo at Weeks 2, 4, 6, 12, and 24 by
chemiluminescent assay. Serum levels of 1,25(OH)2D were
also assessed at baseline and 24 h after the last study drug
injection at Weeks 12 and 24 by extraction chromatography
followed by radioreceptor assay.
Statistical analysis
Treatment group differences for serum and urine phosphate
were compared using an analysis of covariance model, with
actual change as the dependent variable, treatment as a
factor, and baseline value as a covariate. Treatment group
differences for active vitamin D dose were compared using
an analysis of covariance model, with percentage change as
the dependent variable, treatment as a factor, and the
baseline dose as a covariate. A converted active vitamin D
value was used, in which 2 doses of alfacalcidol were
equated to 1 dose of calcitriol [23]. The albumin-corrected
serum calcium levels were measured and calculated as
previously described [19]. The P values for inter-treatment
group comparison of differences were calculated from the
least squares mean difference and standard error.
During the US regulatory review of the rhPTH(1–84)
application for the treatment of patients with hypopar-
athyroidism, the sponsor was requested to re-evaluate the
REPLACE data based on 124 study patients from 31 cen-
ters in North America and Europe, after data from one
clinical site was removed. Mannstadt et al. had reported that
the 134 patients with hypoparathyroidism randomized in the
REPLACE study met the primary efﬁcacy endpoint and had
a generally safe proﬁle [19]. After all comparisons and
analyses were recalculated, there was no change in the
primary endpoint efﬁcacy and safety conclusions, and the
US Prescribing Information cites the data analysis from
124 study patients [24]. This exploratory analysis report
also evaluated the matching 124-patient data set, and for
completeness in data analysis provides the re-analyzed
primary calcium values in the supplementary material.
Results
Of the 124 patients analyzed, 84 were in the rhPTH(1–84)
group and 40 were in the placebo group, reﬂecting the 2:1
randomization. Table 1 summarizes key patient demo-
graphics and baseline characteristics. 79 % of patients were
women. The mean ± SD age was 47.3± 12.7 years, body
mass index was 29.2± 6.1 kg/m2, and duration of hypo-
parathyroidism was 13.6± 10.3 years. Twelve patients
discontinued treatment before study completion: 5 in the
rhPTH(1–84) group and 7 in the placebo group. Of these,
two patients, both in the rhPTH(1–84) group, withdrew
because of an adverse event (one patient had several
adverse events, some of which were judged to be treatment
related; the other patient had a cerebrovascular accident that
was not thought to be related to treatment).
Phosphate levels
At screening, mean± SD serum phosphate level for the
study group was in the upper normal range at 1.5± 0.3
mmol/L (normal range, 0.8–1.6 mmol/L [25]). After opti-
mization, baseline serum phosphate levels were similar for
both treatment groups (1.5 ± 0.2 mmol/L for each). The
time course data in Fig. 1a demonstrate that the serum
phosphate levels in patients receiving rhPTH(1–84),
Endocrine (2017) 55:273–282 275
measured 24 h after the last injection, decreased rapidly
from baseline. At Week 1 (the ﬁrst on-treatment study visit),
serum phosphate had declined by 0.2± 0.02 mmol/L (least
squares mean ± SE). In contrast, in the placebo group,
serum phosphate was unchanged at Week 1 (change from
baseline: 0.0± 0.03 mmol/L; P< 0.001 vs. rhPTH(1–84)).
This initial decrease in serum phosphate with rhPTH(1–84)
was maintained between Weeks 1 and 24, and was sig-
niﬁcantly lower compared with the placebo arm in which
levels remained near baseline. Furthermore, at every study
visit between Weeks 1 and 24, serum phosphate levels
remained stable and were signiﬁcantly lower in the rhPTH
(1–84) treatment arm compared with the placebo arm. At
Week 24, serum phosphate declined by 0.2± 0.02 mmol/L
in rhPTH(1–84)-treated patients and did not change in
placebo-treated patients (change from baseline: 0.0 + 0.03
mmol/L; P < 0.001).
Baseline 24-h urine phosphate excretion levels were
similar in both treatment groups (rhPTH (1–84), 34.2±
14.2 mmol/24 h; placebo, 33.7± 12.0 mmol/24 h). In con-
trast to serum phosphate measurements, urinary phosphate
data showed substantial variability, and no signiﬁcant
change between the groups was apparent until Week 12
(Fig. 1b). At Week 12, the signiﬁcant decrease in urinary
phosphate levels in the rhPTH(1–84) group was 5.4± 1.9
mmol/24 h compared with an increase of 2.4± 3.0 mmol/
24 h in the placebo group (least squares mean ± SE; P=
0.03). At Week 24, 24-h urinary phosphate excretion levels
had decreased in both treatment arms relative to baseline;
the decrease was 6.1± 1.4 mmol/24 h in patients receiving
rhPTH(1–84) compared with a decrease of 2.4± 2.1 mmol/
24 h in patients receiving placebo (P= 0.15).
Calcium–phosphate product levels
Prescribed calcium dose, albumin-corrected serum calcium
and urinary calcium at baseline and Week 24, and time
course data for serum calcium are presented in Supple-
mentary Tables 1 and 2; these data conﬁrm the observed
reductions reported in the primary endpoint study
analysis [19]. At baseline after optimization, mean± SD
calcium–phosphate product levels were similar for both
Table 1 Patient population
characteristics at baseline (after








Mean (range) age, years 46.6 (19–74) 48.9 (21–73)
Women (men), n 65 (19) 33 (7)
Mean± SD body mass index, kg/m2 29.3± 6.4 28.9± 5.3
Duration (range) of hypoparathyroidism, years 14.6 (2–50) 11.6 (2–38)
Baseline characteristics after optimization period
Prescribed calcium, n (%)
0–2000 mg/day 57 (68) 29 (72.5)
>2000 mg/day 27 (32) 11 (27.5)
Mean± SD Mean± SD
Prescribed native vitamin D,a IU/day 2217± 6875 1467± 3971
Prescribed calcitriol,b µg/day 0.9± 0.5 0.8± 0.4
Serum 25(OH)D levels, nmol/L 105.5± 37.0 110.9± 47.4 75–250
Serum 1,25(OH)2D levels, pmol/L 87.6± 55.1 85.0± 29.9 39–156
Calcium parameters
Serum calcium,c mmol/L 2.1± 0.2 2.2± 0.2 2.1–2.6
Urinary calcium, mmol/24 h 9.0± 4.8 8.4± 4.3 1.3–7.5
Phosphate parameters
Serum phosphate, mmol/L 1.5± 0.2 1.5± 0.2 0.8–1.6
Urinary phosphate, mmol/24 h 34.2± 14.2 33.7± 12.0 12.9–42.0
Serum magnesium, mmol/L 0.83± 0.08 0.84± 0.07 0.65–1.05
Calcium–phosphate product, mmol2/L2 3.22± 0.54 3.29± 0.52 <4.4
rhPTH recombinant human parathyroid hormone, ULN upper limit of normal
a Among those patients receiving native vitamin D (rhPTH(1–84), n= 61; placebo, n= 24)
b Alphacalcidol dose is converted to calcitriol dose based on a conversion factor of 2 alphacalcidol equals 1
calcitrio
c Albumin-corrected total serum calcium
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treatment groups (rhPTH(1–84), 3.2± 0.5 mmol2/L2; pla-
cebo, 3.3± 0.5 mmol2/L2; Fig. 2). Calcium–phosphate
product levels decreased rapidly in the rhPTH(1–84) treat-
ment arm; at Week 1, calcium–phosphate product levels
declined to 2.9± 0.5 mmol2/L2. In contrast, the levels in the
placebo group remained steady; Week 1 levels were 3.2±
0.4 mmol2/L2. These values were generally maintained over
the remainder of the study: at Week 24, calcium–phosphate
product levels were 2.8± 0.5 mmol2/L2 in patients receiv-


















































































































































Fig. 1 Change from baseline in
serum phosphate a and urinary
phosphate b during treatment
with rhPTH(1–84) or placebo in
patients with
hypoparathyroidism. Change
from baseline values is least
squares mean± SE. rhPTH=
recombinant human parathyroid
hormone. *P ≤ 0.004 a or P=
0.03 b for the mean change from
baseline for the rhPTH(1–84) vs.
placebo
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receiving placebo. The least squares mean ± SE change in
the calcium–phosphate product from baseline to Week 24
between the treatment arms was signiﬁcantly different: there
was a decrease of 0.4± 0.1 mmol2/L2 in the rhPTH(1–84)
group and a decrease of only 0.1± 0.1 mmol2/L2 in the
placebo group (P< 0.001).
Native vitamin D
When the mean daily dose is calculated from the total dose
over the treatment period, patients on rhPTH(1–84) were on
a higher dose of oral native vitamin D compared with
patients in the placebo group (1487 ± 2127 IU/day vs. 917
± 1312 IU/day; mean ± SD). After optimization, baseline
serum levels of 25(OH)D were within the normal range and
were similar for both treatment groups (Table 1 and
Fig. 3a). Among patients receiving rhPTH(1–84), serum 25
(OH)D levels declined steadily between baseline and Week
12, and then stabilized, whereas in patients receiving pla-
cebo, serum 25(OH)D levels decreased only slightly within
the ﬁrst 4 weeks and stayed near baseline levels. At Weeks
2 and 12, mean ± SD serum 25(OH)D levels declined by
14.1± 18.6 nmol/L and 32.3± 31.8 nmol/L, respectively, in
the rhPTH(1–84) group and remained below baseline until
Week 24 (change from baseline: −24.9± 39.2 nmol/L). In
contrast, there was no change in the placebo group on serum
25(OH)D levels (mean± SD change from baseline at Week
24: −3.1± 33.6 nmol/L).
Activated vitamin D
After optimization, baseline serum levels of 1,25(OH)2D
were within the normal range and were similar for both
treatment groups (Table 1 and Fig. 3b). The mean± SD
baseline active vitamin D dose was 0.9± 0.5 µg/day in
patients receiving rhPTH(1–84) and 0.8± 0.4 µg/day in
patients receiving placebo; 67 and 62 % of patients
treated with rhPTH(1–84) or placebo, respectively, were
taking >0.5 μg/day calcitriol or >1.0 μg/day alfacalcidol.
At the beginning of the treatment period, active vitamin D
doses were reduced per study protocol; in the initial
2 weeks, the reductions were 51± 4 % and 51± 6 % (least
squares mean± SE percentage change from baseline
values), for rhPTH(1–84)-treated and placebo-treated
patients, respectively (Supplementary Fig. 1). Patients
in the rhPTH(1–84) group continued dose reductions until
Week 8 (90± 4% reduction) and ended treatment at Week
24 with a 77± 4 % reduction from baseline. In the
placebo group, the dose decreased by 63± 5 % between
baseline and Week 6 and ended treatment at Week 24 with a
35± 7 % reduction from baseline. By Week 24, dose
reductions from baseline were signiﬁcantly greater for
patients receiving rhPTH(1–84) compared with patients
receiving placebo (P< 0.001); 87 % of patients receiving
rhPTH(1–84) had a ≥50 % reduction in active vitamin D
dose compared with 45 % of patients receiving placebo.




























































Fig. 2 Time course of change in
calcium–phosphate product
during treatment with rhPTH
(1–84) or placebo in patients
with hypoparathyroidism
measured before the next
injection. Values are mean±
SD. rhPTH= recombinant
human parathyroid hormone
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1,25(OH)2D compared with serum 25(OH)D levels. Serum
levels of 1,25(OH)2D remained stable throughout the study
without major changes in both groups (change from
baseline at Week 24 with rhPTH(1–84) and placebo:






























































































Fig. 3 Time course of change in
serum 25-hydroxyvitamin D
a and 1,25-dihydroxyvitamin D
b during treatment with rhPTH
(1–84) or placebo in patients
with hypoparathyroidism.
Values are mean ± SD. rhPTH
= recombinant human
parathyroid hormone
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Among patients who achieved independence from oral
active vitamin D (62 %, rhPTH(1–84); 24 %, placebo),
serum 1,25(OH)2D was maintained with rhPTH(1–84)
treatment but decreased with placebo (change from baseline
at Week 24, increase of 3.2± 52.4 pmol/L, and decrease of
25.0± 27.9 pmol/L, respectively, for these analytes).
Discussion
This analysis of exploratory endpoints from the pivotal
phase III REPLACE study provides further evidence that
rhPTH(1–84) therapy for patients with hypoparathyroidism
is efﬁcacious and has different effects from conventional
treatment on serum phosphate, calcium–phosphate product,
and vitamin D metabolites [19]. Here, we provided detailed
time course data on the rapid changes in phosphate,
calcium–phosphate product, and vitamin D metabolite
levels with rhPTH(1–84) treatment.
On conventional therapy, serum phosphate levels often
exceed the normal range during the day in patients with
hypoparathyroidism [21]. Indeed, mean serum phosphate
levels were in the upper range of normal in both groups at
baseline, reﬂecting the lack of the phosphaturic effect of
PTH [5]. Elevated serum phosphate levels are associated
with a greater risk of soft tissue calciﬁcations, likely via
increases in calcium–phosphate product levels [5, 7,
10–12]. In addition, preclinical studies suggest that high
levels of serum phosphate may directly promote vascular
calciﬁcation via osteochondrogenic conversion of vascular
smooth muscle cells [26]. Among patients with end-stage
renal disease or cardiovascular disease, elevated serum
phosphate levels correlate with increased mortality risk [9,
27]. Our results show that, compared with placebo, rhPTH
(1–84) treatment signiﬁcantly decreased serum phosphate
levels. It is noteworthy that the reductions reported here in
serum phosphate levels and calcium–phosphate product
were noticeable despite the fact that the measurements were
made 24 h after the last PTH injection, a time point that
reﬂects a minimal reduction in serum phosphate and
calcium–phosphate product [21]. In a phase I pharmaco-
dynamic (PD) and pharmacokinetic (PK) study conducted
in patients with hypoparathyroidism, Clarke et al. reported
that reductions in serum phosphate and calcium–phosphate
product occur rapidly following rhPTH(1–84) injection [21]
and were maximal at 12 h following injection with 50–100
µg rhPTH(1–84).
The decline in serum phosphate levels in the rhPTH
(1–84) group was not accompanied by a corresponding
increase in urinary phosphate excretion. Transient changes
in urinary phosphate excretion may have been missed in this
study because of the timing of assessments, and we may
have captured only the new steady state. In the phase I
PK/PD study, serum phosphate decreased to a nadir at 5 h
after injection of rhPTH(1–84), which was associated with a
corresponding increase in urinary fractional excretion of
phosphate over the same time course [21]. Similarly, Sikjaer
et al. showed that urinary phosphate excretion increased
over the ﬁrst 8 h post-injection of rhPTH(1–84), followed
by a return to near-baseline levels over the next 16 h [28]. In
the present study, the ﬁrst post-baseline assessment of
urinary phosphate was conducted after 1 week of rhPTH
(1–84) treatment had been completed and 24 h after the last
study drug dose. By 1 week of treatment with rhPTH(1–84),
new steady-state serum phosphate levels may already be
established, such that no further increases in urinary phos-
phate would be required to maintain the lower serum
phosphate concentrations. Furthermore, while the study
protocol did not restrict patients’ dietary intake or the
administration of phosphate binders, no patient took phos-
phate binders during the study. Thus, ﬂuctuations in
dietary phosphate during the study may also have con-
tributed to the variability in urinary phosphate. Finally,
compared with other time points, fewer patients had urine
phosphate levels assessed at the early study visits
(up to Week 6). The smaller sample sizes at these early time
points may have contributed to the lack of consistent
between-group differences at these time points. None-
theless, the urinary phosphate data presented here might
inform future studies investigating phosphate dynamics in
hypoparathyroidism.
Although no prospective data exist in the hypopar-
athyroidism population, a somewhat arbitrary threshold of
4.4 mmol2/L2 (55 mg²/dL²) is generally accepted as the
upper limit of normal, and recent treatment guidelines
include maintenance of calcium–phosphate product below
that level as a goal of hypoparathyroidism management [13,
14]. Overall, our analysis showed that levels of
calcium–phosphate product decreased to a greater extent in
the rhPTH(1–84) group than in the placebo group. Fur-
thermore, calcium–phosphate product levels declined
rapidly with rhPTH(1–84) within 1 week of treatment.
Decreases in calcium–phosphate product were evident with
rhPTH(1–84) treatment despite the fact that serum calcium
levels remained stable during the study. The observed
reductions in calcium–phosphate product were likely driven
primarily by rhPTH(1–84)-mediated decreases in serum
phosphate. Together, these data suggest that, unlike con-
ventional management strategies with oral calcium and
active vitamin D therapy, treatment with rhPTH(1–84)
improves phosphate levels and calcium–phosphate product
in patients with hypoparathyroidism. Thus, rhPTH(1–84)
has the potential to reduce complications, such as soft tissue
calciﬁcation, compared with conventional therapy by more
effectively restoring the full range of physiologic activities
elicited by the endogenous hormone.
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The 2–16-week optimization period before randomiza-
tion in the REPLACE study ensured that patients had
optimized their conventional treatment with oral calcium
and calcitriol or alfacalcidol and had normal serum 25(OH)D
and magnesium levels. As a result, serum levels for both
25(OH)D and 1,25(OH)2D were within the normal range at
baseline. Despite signiﬁcant reductions in oral active vita-
min D or even complete independence of active vitamin D
in a subgroup, patients treated with rhPTH(1–84) main-
tained serum levels of the active vitamin D metabolite
1,25(OH)2D in the normal range. In contrast, placebo-
treated patients who eliminated oral active vitamin D
experienced decreases in serum 1,25(OH)2D. This reﬂects
the physiologic role of PTH to enhance conversion of
25(OH)D to 1,25(OH)2D. In addition, other metabolic
pathways may be contributing to the turnover of 25(OH)D
in patients treated with rhPTH(1–84), including catabolism
by cytochrome P450 (CYP) 24A1 to generate 24,25(OH)2D
[29]. In some cell types, CYP24A1 is known to be activated
by PTH [29]. Because 25(OH)D constitutes the substrate for
conversion to active vitamin D, care has to be taken to keep
25(OH)D levels within the normal range in these patients.
Consequently, over the course of the study, patients
receiving rhPTH(1–84) had higher daily requirements for
supplemental native vitamin D than patients receiving pla-
cebo, although the variability was large. Thus, administra-
tion of rhPTH(1–84) may permit reduction or elimination of
oral calcium and active vitamin D supplementation, but
native vitamin D supplementation should be continued. In
practice, careful monitoring of serum 25(OH)D levels, as
well as adjustments of oral native vitamin D supplementa-
tion as necessary, is warranted for patients receiving
rhPTH(1–84).
The results reported here are consistent with other pub-
lished data using different study designs and dosing regi-
mens of rhPTH(1–84) [18, 20]. Cusano et al. reported that,
among 27 patients treated with rhPTH(1–84) 100 μg every
other day, serum phosphate levels decreased from 1.4± 0.6
mmol/L at baseline to approximately 1.3 mmol/L at 4 years
and remained in the normal range throughout the study [18].
In a study of add-on rhPTH(1–84) therapy to standard
treatment, Sikjaer et al. reported that serum phosphate levels
decreased from 1.1 mmol/L at baseline to less than 1.0
mmol/L in 32 patients receiving rhPTH(1–84) 100 μg every
day at 24 weeks [20]. Overall, median serum 25(OH)D was
72 nmol/L at baseline and did not change during the study.
Serum 1,25(OH)2D was 98 pmol/L at baseline and
increased rapidly in patients receiving rhPTH(1–84). Simi-
lar to our observations, levels in the Sikjaer study remained
stable throughout that study, despite the marked dose
reduction in active vitamin D (median reduction, 50 and
0 % in patients treated with rhPTH(1–84) and placebo,
respectively; P< 0.001).
As previously mentioned, a limitation in the REPLACE
study was that serum phosphate and 1,25(OH)2D levels
were measured 24 h after the last injection; therefore, we
likely missed the maximal decrease of serum phosphate and
calcium–phosphate product and the maximal increase in
1,25(OH)2D levels during the ﬁrst 8 h.
The REPLACE study demonstrated that daily SC treat-
ment with rhPTH(1–84) allowed reductions in the large
amounts of oral calcium and active vitamin D generally
required for symptom management without increasing
urinary calcium excretion [19]. This current analysis
extends the primary ﬁndings of the REPLACE study and
provides further mechanistic evidence that therapy with
rhPTH(1–84), in contrast to conventional therapy with oral
calcium and active vitamin D, mimics the action of endo-
genous PTH in patients with hypoparathyroidism [12]. In
summary, treatment with rhPTH(1–84) addresses the mul-
tiple physiologic mineral and vitamin D abnormalities that
occur in hypoparathyroidism by decreasing serum phos-
phate levels toward the mid-normal range, improving
the calcium–phosphate product, and maintaining serum
1,25(OH)2D levels in the normal range. This latter beneﬁt
will be maintained if careful monitoring of serum 25(OH)D
levels and adjustments in oral native vitamin D supple-
mentation as necessary are performed by the treating
endocrinologist.
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